Bauml JM, et al. - Researchers compared the outcomes of patients treated for head and neck squamous cell carcinoma (HNSCC) with radiation therapy (RT) plus cisplatin vs cetuximab. Using Veterans Health Affairs data, they identified 4,520 patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016. Outcomes suggest that for the nonoperative management of stage III to IVb HNSCC, RT with cetuximab yields inferior OS vs cisplatin. Findings thus suggest cisplatin to be the most appropriate adjunct for RT in this setting.